Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28861775 | 0.90 | POLB (0.61) | KMT2APOLBSMN1; SMN2CA12CA1 | |
| SCHEMBL4391646 | 0.85 | POLB (0.71) | KMT2APOLBSMN1; SMN2CA12CA1 | |
| SCHEMBL4508859 | 0.84 | KMT2A (0.90) | KMT2APOLBSMN1; SMN2CA12CA1 | |
| SCHEMBL12995570 | 0.83 | POLB (0.69) | KMT2APOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL654537 | 0.83 | POLB (0.69) | KMT2APOLBSMN1; SMN2CA12CA2 | |
| SCHEMBL656477 | 0.83 | RAB9A (0.71) | KMT2APOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL698365 | 0.83 | NPC1 (0.71) | KMT2APOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL11925392 | 0.83 | KMT2A (0.71) | KMT2APOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL656655 | 0.83 | POLB (0.97) | POLBSMN1; SMN2GLANPC1RAB9A | |
| SCHEMBL491293 | 0.83 | KMT2A (1.00) | KMT2ASMN1; SMN2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079899-A | Application of pharmaceutical composition in preparation of medicines for preventing or treating diseases related to Sirttail 7 protein | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2024175081-A1 | SHP2 INHIBITOR COMPOUND AND USE THEREOF | 深圳真实生物医药科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| EP-4269394-A1 | BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2023-11-01 | — | — | EP | disclosed |
| CN-116829542-A | Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salts, preparation method thereof and pharmaceutical composition containing same as active ingredient | 韩国化学研究院 | 2023-09-29 | — | — | CN | disclosed |
| EP-3331864-A2 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2018-06-13 | — | — | EP | disclosed |
| EP-2937341-B1 | 4-(BENZYL)-PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-05 | — | — | EP | disclosed |
| EP-2937341-A1 | 4-(BENZYL)-PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS | Janssen Pharmaceutica N.V. (BE) | 2015-10-28 | — | — | EP | disclosed |
| US-9169224-B2 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-27 | — | — | US | disclosed |
| EP-1836179-B1 | PIPERIDINE- AND PIPERAZINE-1-CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-06 | — | — | EP | disclosed |
| CN-103764658-A | Compounds, their pharmaceutical compositions and their uses as IDH1 mutants inhibitors for treating cancers | AGIOS PHARMACEUTICALS INC | 2014-04-30 | — | — | CN | disclosed |
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2007-07-12 | — | — | US | disclosed |
| US-20060079498-A1 | Therapeutic compounds | PFIZER INC | 2006-04-13 | — | — | US | disclosed |
| US-6710043-B1 | POSSESS THE POTENTIATION OF THE CHOLINERGIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20040014745-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1235575-A2 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
| WO-2000072834-A9 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-12-20 | — | — | WO | disclosed |
| EP-1140836-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000072834-A2 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000042011-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | SLC5A2, SLC5A1, REN | KMT2A 2117/4885POLB 4687/4885SMN1; SMN2 2350/4885 |
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | CTSF, CTSS, CSTB | KMT2A 3063/4885POLB 3763/4885SMN1; SMN2 3114/4885 |
| US-20060079498-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | KMT2A 2117/4885POLB 4687/4885SMN1; SMN2 2350/4885 |
| US-20040014745-A1 | Amide compounds | CHRM1, CHRM2, CHRNE | KMT2A 1224/4885POLB 2764/4885SMN1; SMN2 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.